Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2023
Total Revenue
▼$1.5B
Program Spending
69%
of total expenses go to program services
Total Contributions
$583.1M
Total Expenses
▼$1.3B
Total Assets
$4.7B
Total Liabilities
▼$1.7B
Net Assets
$3.1B
Officer Compensation
→$2.6M
Other Salaries
$666.5M
Investment Income
$237.1M
Fundraising
▼$0
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$4.5M
VA/DoD Award Count
7
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding
$21.5M
Awards Found
24
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Department of Health and Human Services | IMPACT OF HIV-1 FITNESS ON DISEASE PROGRESSION | $5.2M | FY2007 | Aug 2007 – Apr 2025 |
| Department of Health and Human Services | HYPERPOLARIZED 13C MRI OF PLACENTAL METABOLIC ABNORMALITIES RESULTING FROM THE WESTERN DIET | $2.8M | FY2015 | Sep 2015 – Aug 2021 |
| Department of Health and Human Services | VIRAL AND HOST FACTORS IN NEUROINVASION OF ENCEPHALITIS ALPHAVIRUSES - SUMMARY THE LONG-TERM OBJECTIVE OF THIS MULTI-PI PROJECT IS TO DETERMINE HOW HOST-PATHOGEN INTERACTIONS IMPACT ENTRY, INFECTION, AND SPREAD OF ENCEPHALITIC ALPHAVIRUSES IN THE CENTRAL NERVOUS SYSTEM (CNS). THE VECTOR-BORNE NEUROTROPIC VIRUSES, VENEZUELAN, EASTERN, AND WESTERN EQUINE ENCEPHALITIS VIRUSES (VEEV, EEEV, WEEV), INVADE THE CNS AFTER SUBCUTANEOUS INOCULATION AND INITIAL INTERACTION WITH IMMUNE SENTINEL CELLS, SUCH AS MACROPHAGES AND DENDRITIC CELLS (DCS) (VEEV), OR FIBROBLASTIC, OSTEOBLASTIC AND OTHER CELL TYPES (EEEV, WEEV). BOTH EEEV AND VEEV ENTER THE BRAIN VIA THE HEMATOGENOUS ROUTE BUT ONLY VEEV IS FOUND IN OLFACTORY NEURONS. THE CNS LACKS INTRAPARENCHYMAL LYMPHOID TISSUES AND CANNOT INITIATE ADAPTIVE IMMUNE RESPONSES; THUS, IT MAINLY RELIES ON INNATE RESPONSES COMMUNICATED THROUGH LOCAL AND SYSTEMIC CYTOKINE SECRETION, WHICH MODULATE THE STATUS OF RESIDENT NEURAL CELLS AND LIMITS VIRAL NEUROINVASION AND THE EXTENT OF INFECTION. CNSRESIDENT CELLS MAY INCLUDE MULTIPLE MEMBERS OF THE NEUROVASCULAR UNIT (NVU) SUCH AS BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BMECS), PERICYTES, ASTROCYTES, MICROGLIA AND NEURONS THEMSELVES THAT MAY BE INFECTED DIRECTLY OR ACTED UPON BY REGIONALLY OR SYSTEMICALLY PRODUCED CYTOKINES. VEEV IS A HIGHLY LYMPHOTROPIC VIRUS ELICITING ROBUST SERUM CYTOKINE RESPONSES AFTER PERIPHERAL INOCULATION, WHILE EEEV TROPISM IN LYMPHOID TISSUES IS HIGHLY RESTRICTED, AND SERUM CYTOKINE RESPONSES ARE MUCH LOWER, AND IN THE CASE OF TYPE I IFN, OFTEN UNDETECTABLE. IN PUBLISHED STUDIES, TWO PRIMARY VIRULENCE FACTORS FOR EEEV IN HUMAN AND MURINE MODELS DEFINED MECHANISMS THAT SUPPRESSES REPLICATION IN IMMUNE SENTINEL MYELOID CELLS AND GREATLY LIMIT INNATE IMMUNE (ESPECIALLY INTERFERON) RESPONSES TO EEEV INFECTION IN VITRO AND IN VIVO1. HOW THESE FACTORS, WHICH INCLUDE THE PRESENCE OF BINDING SITES FOR THE HEMATOPOIETIC CELL-SPECIFIC MICRORNA, MIR142-3P, IN THE EEEV 3' UNTRANSLATED REGION (UTR)1-3, AND EFFICIENT BINDING OF EEEV TO HEPARAN SULFATE (HS) RECEPTORS ON CELLS4,5, IMPACT THE DIFFERENTIAL NEUROINVASION AND CNS DISSEMINATION OF EEEV VERSUS VEEV IS UNKNOWN. SUPPORTING THE IDEA THAT DIFFERENCES IN EEEV VERSUS VEEV CYTOKINE INDUCTION MAY BE CRITICAL TO NEUROINVASION, WE FOUND THAT TYPE I IFN-DEPENDENT RESPONSES DIRECTLY REGULATE TRANSCYTOSIS, PREVENTING ALPHAVIRUS ENTRY ACROSS THE BBB AND MODULATING THE LEVEL OF INFECTION AND INJURY IN CELLS OF THE NVU6. THUS, SYSTEMIC AND LOCAL CYTOKINE RESPONSES DURING ALPHAVIRUS INFECTION INDUCE BMECS AND PERICYTES TO REGULATE VIRAL ENTRY AT THE BLOOD-BRAIN BARRIER (BBB) AND POTENTIALLY OTHER CNS SITES. THIS IS CONSISTENT WITH THE RELATIVE EXTENT OF VIRUS REPLICATION AT TERMINAL STAGES OF DISEASE AS EEEV EXHIBITS WIDESPREAD INFECTION OF NEURONS THROUGHOUT THE CNS WHILE VEEV REPLICATION IS MUCH MORE FOCAL (UNPUBLISHED). USING MUTANT VEEV AND EEEV, NOVEL VIRAL VECTORS THAT EXPRESS INDICATORS OF INFECTION (E.G., EGFP, NANOLUCIFERASE) IN VIVO, WE HAVE OBSERVED REGIONAL HETEROGENEITY IN DOMINANT SITES OF ENTRY BETWEEN THESE ALPHAVIRUSES. WITH REGARD TO BBB ENTRY, OUR STUDIES ALSO INDICATE THAT VIRAL NEUROINVASION PRECEDES BBB DISRUPTION, UTILIZING CAVEOLIN-MEDIATED TRANSCYTOSIS TO CROSS THE BBB. WE HYPOTHESIZE THAT TYPE I INTERFERON RESPONSES DIFFERENTIALLY IMPACT THE ENTRY AND INFECTION OF EEEV AND VEEV AT THE NVU VIA VIRUS-SPECIFIC INDUCTION OF REPLICATION-RESTRICTING INNATE IMMUNE RESPONSES. TO TEST THESE HYPOTHESES WE WILL: AIM 1. DEFINE ALPHAVIRUS AND HOST SPECIFIC MECHANISM IN VITRO THAT REGULATE VIRAL ENTRY AND INFECTION AT THE NVU. AIM 2: DEFINE THE IN VIVO FUNCTIONAL ROLE OF TYPE I IFN IN PROTECTION FROM ALPHAVIRUS NEUROINVASION AT THE NVU. | $2.3M | FY2022 | Jul 2022 – Jun 2027 |
| VA/DoDDepartment of Defense | NEXT-GENERATION HUMANIZED MICE TO INVESTIGATE HOW TBI INTERACTS WITH GENETIC RISK FACTORS TO TRIGGER DEMENTIA. | $1.3M | FY2020 | Sep 2020 – Aug 2025 |
| VA/DoDDepartment of Defense | ADVANCED DEVELOPMENT OF A THERAPEUTIC HUMANIZED ANTI-INFLAMMATORY ANTIBODY | $1.1M | FY2010 | Sep 2010 – Jun 2018 |
| National Aeronautics and Space Administration | IMPROVING OUR UNDERSTANDING OF THE NEAR-EARTH METEOROID ENVIRONMENT IS VITAL TO THE SAFETY AND SURVIVABILITY OF NASA SPACECRAFT. RISK ASSESSMENTS FOR | $1M | FY2011 | Jan 2011 – Feb 2015 |
| National Aeronautics and Space Administration | THE OVERARCHING GOALS OF THIS COLLABORATIVE PROGRAM ARE: 1. TO CHARACTERIZE AND MODEL QUANTITATIVELY METEOR MEASUREMENTS WITH A FOCUS ON ESTABLISHING BIASES AND THEREFORE DEFINE THE "TRUE" METEOROID ENVIRONMENT 2. ESTABLISH ESTIMATES OF UNCERTAINTIES FOR MEASURED QUANTITIES RELATED TO THE METEOROID ENVIRONMENT 3. PROVIDE OPERATIONAL SITUATIONAL AWARENESS OF THE METEOROID ENVIRONMENT. | $966K | FY2018 | Mar 2018 – Feb 2021 |
| National Aeronautics and Space Administration | A JOINT PROGRAM FOR METEOROID ENVIRONMENT CHARACTERIZATION AND MODELLING | $950.8K | FY2021 | Mar 2021 – Feb 2024 |
| National Aeronautics and Space Administration | MONITORING AND MODELING OF THE METEOROID ENVIRONMENT IS VITAL TO THE SAFETY AND SURVIVABILITY OF SPACECRAFT. ENGINEERING DESIGN OF SPACECRAFT TO MITI | $835K | FY2015 | Mar 2015 – Feb 2018 |
| National Aeronautics and Space Administration | A JOINT PROGRAM FOR METEOROID MEASUREMENT MODELLING AND MONITORING | $833K | FY2024 | Feb 2024 – Feb 2027 |
| VA/DoDDepartment of Defense | TARGETING LUNG-DERIVED PROTEINS AS A THERAPEUTIC STRATEGY AGAINST BREAST CANCER METASTASIS | $810.4K | FY2017 | Aug 2017 – Aug 2021 |
| VA/DoDDepartment of Defense | CHARACTERIZING THE AGGRESSIVENESS OF PROSTATE CANCER WITH MULTIMODALITY IMAGING | $730.5K | FY2019 | Sep 2019 – Aug 2024 |
| Department of Health and Human Services | NON-INVASIVE MONITORING OF CRISPR/CAS-EDITED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELLS WITH REPORTER GENE-BASED MAGNETIC RESONANCE IMAGING AND POSITRON EMISSION TOMOGRAPHY - PROJECT SUMMARY/ABSTRACT CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS/CRISPR ASSOCIATED NUCLEASE (CRISPR/CAS) GENOME EDITING HAS ENABLED SCIENTISTS TO DESIGN AND BUILD NEXT-GENERATION CELL-BASED THERAPIES. T CELL-BASED IMMUNOTHERAPIES ARE PARTICULARLY SUITABLE CRISPR/CAS TOOLS AS AFTER EDITING THEY CAN BE EXPANDED TO SUFFICIENT NUMBERS FOR USE IN HUMANS. RECENT EFFORTS HAVE SHOWN THAT PRECISE CRISPR/CAS KNOCK-IN AT THE T CELL RECEPTOR A CONSTANT (TRAC) LOCUS WITH A CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETED TOWARDS THE B CELL ANTIGEN CD19 IS MORE EFFECTIVE OVER RANDOMLY INTEGRATING VIRAL-BASED ENGINEERED CAR-T CELLS IN MOUSE MODELS OF HUMAN B CELL LEUKEMIA. THEREFORE, WHILE CRISPR/CAS CELLULAR THERAPIES MAY IMPROVE PATIENT OUTCOMES, LIKE TRADITIONAL CAR- T CELL THERAPY, IT IS NOT KNOWN IF EVERY PATIENT WILL RESPOND EQUIVALENTLY OR IF SOME PATIENTS WILL BE PRONE TO OFF- TARGET, LIFE-THREATENING SIDE EFFECTS. WHAT IS NEEDED ARE TRANSLATIONALLY-RELEVANT TECHNOLOGIES THAT CAN MONITOR THE FATE OF CRISPR/CAS-EDITED CAR-T CELLS IN VIVO TO PROVIDE THE INFORMATION NEEDED TO UNDERSTAND PATIENT TREATMENT RESPONSE/NON-RESPONSE, RELAPSE AND/OR TOXICITY. THE LONG-TERM OBJECTIVE OF THIS APPLICATION IS TO DEVELOP MOLECULAR IMAGING REPORTER GENE TECHNOLOGIES FOR NON-INVASIVE VISUALIZATION OF TRAC-TARGETED CAR-T CELLS IN PATIENTS. SPECIFICALLY, WE PROPOSE TO DEVELOP NOVEL TRANSLATIONALLY-RELEVANT MAGNETIC RESONANCE IMAGING (MRI) AND POSITRON EMISSION TOMOGRAPHY (PET) REPORTER GENE ASSAYS TO NONINVASIVELY TRACK THE FATE OF TRAC-EDITED CAR-T CELLS OVER TIME AND TO VALIDATE THESE TECHNOLOGIES IN PRECLINICAL MOUSE MODELS. THE SPECIFIC AIMS OF THIS NEW APPLICATION ARE: TO COMPARE MINICIRCLE AND NON-INTEGRATING LENTIVIRAL CRISPR/CAS DONOR VECTORS FOR THEIR ABILITY TO EFFICIENTLY EDIT T CELLS AT THE TRAC LOCI WITH A CD19-TARGETED CAR (AIM 1.1); TO DEVELOP DONOR VECTORS CO-ENCODING OUR CAR, A BIOLUMINESCENCE REPORTER GENE, AND EITHER THE HUMAN MRI REPORTER ORGANIC ANION TRANSPORTER POLYPEPTIDE 1B3 (OATP1B3) OR THE PET REPORTER SODIUM IODIDE SYMPORTER (NIS), AND TO VALIDATE TRAC-EDITING AND FUNCTIONAL REPORTER EXPRESSION IN VITRO (AIM 1.2); TO EVALUATE THE SENSITIVITY OF OATP1B3-BASED MRI AND NIS-BASED PET FOR VISUALIZING CAR-T CELLS IN VIVO, AS WELL AS PERFORM LONGITUDINAL PET AND MRI OF CAR-T CELLS IN MOUSE MODELS OF B CELL MALIGNANCIES (AIM 2.1); AND FINALLY, TO DEVELOP A DUAL-REPORTER TRANSLATIONALLY-RELEVANT CRISPR/CAS SYSTEM AND EVALUATE THE ABILITY TO NONINVASIVELY MONITOR CAR-T CELLS IN MICE WITH BOTH PET AND MRI (AIM 2.2). THE SIGNIFICANCE OF THIS WORK WILL BE TO PROVIDE POWERFUL CELL TRACKING TECHNOLOGIES TO ALLOW THE FATE OF CRISPR/CAS-EDITED CAR-T CELLS, OR OTHER CRISPR/CAS-EDITED CELLULAR THERAPIES, TO BE MONITORED NONINVASIVELY IN PRECLINICAL MODELS AND PATIENTS. THIS INFORMATION WILL ALLOW MORE PRECISE MONITORING OF THESE TRANSFORMATIVE THERAPIES IN INDIVIDUAL PATIENTS TO BETTER ASSESS SAFETY AS WELL AS TO RELATE CELL BIODISTRIBUTION TO PATIENT OUTCOMES. | $656.1K | FY2019 | Sep 2019 – Jul 2024 |
| Department of the Interior | D18AC00035 | $503.2K | FY2018 | Sep 2018 – Mar 2020 |
| VA/DoDDepartment of Defense | ADVANCED DEVELOPMENT OF A THERAPEUTIC, HUMANIZED, ANTI-INFLAMMATORY ANTIBODY | $479.6K | FY2010 | Sep 2010 – Aug 2014 |
| Department of Health and Human Services | MICROVASCULAR O2 DELIVERY: IMPACT OF ERYTHROCYTE-RELEASED ATP | $414.1K | FY2007 | Aug 2007 – Jun 2010 |
| Department of Health and Human Services | NON-INVASIVE MONITORING OF CRISPR/CAS-EDITED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELLS WITH REPORTER GENE-BASED MAGNETIC RESONANCE IMAGING AND POSITRON EMISSION TOMOGRAPHY | $314.6K | FY2019 | Sep 2019 – Jul 2021 |
| Department of Health and Human Services | ROLE OF OVO-LIKE 1 IN THE REGULATION OF HUMAN TROPHOBLAST DIFFERENTIATION | $109.3K | FY2014 | Sep 2014 – Mar 2017 |
| VA/DoDDepartment of Defense | USING GENETIC BUFFERING RELATIONSHIPS IDENTIFIED IN FISSION YEAST TO ELUCIDATE THE MOLECULAR PATHOLOGY OF TUBEROUS SCLEROSIS | $84.3K | FY2014 | Jul 2014 – Jun 2017 |
| Department of Health and Human Services | ENGINEERING A CHIMERIC SERPIN AS A PREVENTIVE THERAPEUTIC FOR ISCHEMIC STROKE | $74.1K | FY2008 | Mar 2008 – May 2010 |
| VA/DoDDepartment of Defense | CSP - INTERNATIONAL CONFERENCE ON AUDITORY CORTEX | $18.9K | FY2017 | Jul 2017 – Oct 2017 |
| Department of State | TO FUND THE TRAVEL COSTS FOR UP TO FOUR U.S. SPEAKERS. | $8,000 | FY2017 | Sep 2017 – Oct 2018 |
| Department of State | GRANT WILL SUPPORT U.S. RELATED CONFERENCE ENTITLED "STATES OF EMERGENCY: CRISIS PANIC AND NATION." THE CONFERENC WILL FOCUS ON HOW AMERICANS HAVE H | $6,278 | FY2009 | Sep 2009 – Nov 2009 |
| National Aeronautics and Space Administration | EXTENSIVE METERIOD OBSERVATION | -$10.1K | FY2011 | Apr 2011 – Apr 2011 |
Department of Health and Human Services
$5.2M
IMPACT OF HIV-1 FITNESS ON DISEASE PROGRESSION
Department of Health and Human Services
$2.8M
HYPERPOLARIZED 13C MRI OF PLACENTAL METABOLIC ABNORMALITIES RESULTING FROM THE WESTERN DIET
Department of Health and Human Services
$2.3M
VIRAL AND HOST FACTORS IN NEUROINVASION OF ENCEPHALITIS ALPHAVIRUSES - SUMMARY THE LONG-TERM OBJECTIVE OF THIS MULTI-PI PROJECT IS TO DETERMINE HOW HOST-PATHOGEN INTERACTIONS IMPACT ENTRY, INFECTION, AND SPREAD OF ENCEPHALITIC ALPHAVIRUSES IN THE CENTRAL NERVOUS SYSTEM (CNS). THE VECTOR-BORNE NEUROTROPIC VIRUSES, VENEZUELAN, EASTERN, AND WESTERN EQUINE ENCEPHALITIS VIRUSES (VEEV, EEEV, WEEV), INVADE THE CNS AFTER SUBCUTANEOUS INOCULATION AND INITIAL INTERACTION WITH IMMUNE SENTINEL CELLS, SUCH AS MACROPHAGES AND DENDRITIC CELLS (DCS) (VEEV), OR FIBROBLASTIC, OSTEOBLASTIC AND OTHER CELL TYPES (EEEV, WEEV). BOTH EEEV AND VEEV ENTER THE BRAIN VIA THE HEMATOGENOUS ROUTE BUT ONLY VEEV IS FOUND IN OLFACTORY NEURONS. THE CNS LACKS INTRAPARENCHYMAL LYMPHOID TISSUES AND CANNOT INITIATE ADAPTIVE IMMUNE RESPONSES; THUS, IT MAINLY RELIES ON INNATE RESPONSES COMMUNICATED THROUGH LOCAL AND SYSTEMIC CYTOKINE SECRETION, WHICH MODULATE THE STATUS OF RESIDENT NEURAL CELLS AND LIMITS VIRAL NEUROINVASION AND THE EXTENT OF INFECTION. CNSRESIDENT CELLS MAY INCLUDE MULTIPLE MEMBERS OF THE NEUROVASCULAR UNIT (NVU) SUCH AS BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BMECS), PERICYTES, ASTROCYTES, MICROGLIA AND NEURONS THEMSELVES THAT MAY BE INFECTED DIRECTLY OR ACTED UPON BY REGIONALLY OR SYSTEMICALLY PRODUCED CYTOKINES. VEEV IS A HIGHLY LYMPHOTROPIC VIRUS ELICITING ROBUST SERUM CYTOKINE RESPONSES AFTER PERIPHERAL INOCULATION, WHILE EEEV TROPISM IN LYMPHOID TISSUES IS HIGHLY RESTRICTED, AND SERUM CYTOKINE RESPONSES ARE MUCH LOWER, AND IN THE CASE OF TYPE I IFN, OFTEN UNDETECTABLE. IN PUBLISHED STUDIES, TWO PRIMARY VIRULENCE FACTORS FOR EEEV IN HUMAN AND MURINE MODELS DEFINED MECHANISMS THAT SUPPRESSES REPLICATION IN IMMUNE SENTINEL MYELOID CELLS AND GREATLY LIMIT INNATE IMMUNE (ESPECIALLY INTERFERON) RESPONSES TO EEEV INFECTION IN VITRO AND IN VIVO1. HOW THESE FACTORS, WHICH INCLUDE THE PRESENCE OF BINDING SITES FOR THE HEMATOPOIETIC CELL-SPECIFIC MICRORNA, MIR142-3P, IN THE EEEV 3' UNTRANSLATED REGION (UTR)1-3, AND EFFICIENT BINDING OF EEEV TO HEPARAN SULFATE (HS) RECEPTORS ON CELLS4,5, IMPACT THE DIFFERENTIAL NEUROINVASION AND CNS DISSEMINATION OF EEEV VERSUS VEEV IS UNKNOWN. SUPPORTING THE IDEA THAT DIFFERENCES IN EEEV VERSUS VEEV CYTOKINE INDUCTION MAY BE CRITICAL TO NEUROINVASION, WE FOUND THAT TYPE I IFN-DEPENDENT RESPONSES DIRECTLY REGULATE TRANSCYTOSIS, PREVENTING ALPHAVIRUS ENTRY ACROSS THE BBB AND MODULATING THE LEVEL OF INFECTION AND INJURY IN CELLS OF THE NVU6. THUS, SYSTEMIC AND LOCAL CYTOKINE RESPONSES DURING ALPHAVIRUS INFECTION INDUCE BMECS AND PERICYTES TO REGULATE VIRAL ENTRY AT THE BLOOD-BRAIN BARRIER (BBB) AND POTENTIALLY OTHER CNS SITES. THIS IS CONSISTENT WITH THE RELATIVE EXTENT OF VIRUS REPLICATION AT TERMINAL STAGES OF DISEASE AS EEEV EXHIBITS WIDESPREAD INFECTION OF NEURONS THROUGHOUT THE CNS WHILE VEEV REPLICATION IS MUCH MORE FOCAL (UNPUBLISHED). USING MUTANT VEEV AND EEEV, NOVEL VIRAL VECTORS THAT EXPRESS INDICATORS OF INFECTION (E.G., EGFP, NANOLUCIFERASE) IN VIVO, WE HAVE OBSERVED REGIONAL HETEROGENEITY IN DOMINANT SITES OF ENTRY BETWEEN THESE ALPHAVIRUSES. WITH REGARD TO BBB ENTRY, OUR STUDIES ALSO INDICATE THAT VIRAL NEUROINVASION PRECEDES BBB DISRUPTION, UTILIZING CAVEOLIN-MEDIATED TRANSCYTOSIS TO CROSS THE BBB. WE HYPOTHESIZE THAT TYPE I INTERFERON RESPONSES DIFFERENTIALLY IMPACT THE ENTRY AND INFECTION OF EEEV AND VEEV AT THE NVU VIA VIRUS-SPECIFIC INDUCTION OF REPLICATION-RESTRICTING INNATE IMMUNE RESPONSES. TO TEST THESE HYPOTHESES WE WILL: AIM 1. DEFINE ALPHAVIRUS AND HOST SPECIFIC MECHANISM IN VITRO THAT REGULATE VIRAL ENTRY AND INFECTION AT THE NVU. AIM 2: DEFINE THE IN VIVO FUNCTIONAL ROLE OF TYPE I IFN IN PROTECTION FROM ALPHAVIRUS NEUROINVASION AT THE NVU.
Department of Defense
$1.3M
NEXT-GENERATION HUMANIZED MICE TO INVESTIGATE HOW TBI INTERACTS WITH GENETIC RISK FACTORS TO TRIGGER DEMENTIA.
Department of Defense
$1.1M
ADVANCED DEVELOPMENT OF A THERAPEUTIC HUMANIZED ANTI-INFLAMMATORY ANTIBODY
National Aeronautics and Space Administration
$1M
IMPROVING OUR UNDERSTANDING OF THE NEAR-EARTH METEOROID ENVIRONMENT IS VITAL TO THE SAFETY AND SURVIVABILITY OF NASA SPACECRAFT. RISK ASSESSMENTS FOR
National Aeronautics and Space Administration
$966K
THE OVERARCHING GOALS OF THIS COLLABORATIVE PROGRAM ARE: 1. TO CHARACTERIZE AND MODEL QUANTITATIVELY METEOR MEASUREMENTS WITH A FOCUS ON ESTABLISHING BIASES AND THEREFORE DEFINE THE "TRUE" METEOROID ENVIRONMENT 2. ESTABLISH ESTIMATES OF UNCERTAINTIES FOR MEASURED QUANTITIES RELATED TO THE METEOROID ENVIRONMENT 3. PROVIDE OPERATIONAL SITUATIONAL AWARENESS OF THE METEOROID ENVIRONMENT.
National Aeronautics and Space Administration
$950.8K
A JOINT PROGRAM FOR METEOROID ENVIRONMENT CHARACTERIZATION AND MODELLING
National Aeronautics and Space Administration
$835K
MONITORING AND MODELING OF THE METEOROID ENVIRONMENT IS VITAL TO THE SAFETY AND SURVIVABILITY OF SPACECRAFT. ENGINEERING DESIGN OF SPACECRAFT TO MITI
National Aeronautics and Space Administration
$833K
A JOINT PROGRAM FOR METEOROID MEASUREMENT MODELLING AND MONITORING
Department of Defense
$810.4K
TARGETING LUNG-DERIVED PROTEINS AS A THERAPEUTIC STRATEGY AGAINST BREAST CANCER METASTASIS
Department of Defense
$730.5K
CHARACTERIZING THE AGGRESSIVENESS OF PROSTATE CANCER WITH MULTIMODALITY IMAGING
Department of Health and Human Services
$656.1K
NON-INVASIVE MONITORING OF CRISPR/CAS-EDITED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELLS WITH REPORTER GENE-BASED MAGNETIC RESONANCE IMAGING AND POSITRON EMISSION TOMOGRAPHY - PROJECT SUMMARY/ABSTRACT CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS/CRISPR ASSOCIATED NUCLEASE (CRISPR/CAS) GENOME EDITING HAS ENABLED SCIENTISTS TO DESIGN AND BUILD NEXT-GENERATION CELL-BASED THERAPIES. T CELL-BASED IMMUNOTHERAPIES ARE PARTICULARLY SUITABLE CRISPR/CAS TOOLS AS AFTER EDITING THEY CAN BE EXPANDED TO SUFFICIENT NUMBERS FOR USE IN HUMANS. RECENT EFFORTS HAVE SHOWN THAT PRECISE CRISPR/CAS KNOCK-IN AT THE T CELL RECEPTOR A CONSTANT (TRAC) LOCUS WITH A CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETED TOWARDS THE B CELL ANTIGEN CD19 IS MORE EFFECTIVE OVER RANDOMLY INTEGRATING VIRAL-BASED ENGINEERED CAR-T CELLS IN MOUSE MODELS OF HUMAN B CELL LEUKEMIA. THEREFORE, WHILE CRISPR/CAS CELLULAR THERAPIES MAY IMPROVE PATIENT OUTCOMES, LIKE TRADITIONAL CAR- T CELL THERAPY, IT IS NOT KNOWN IF EVERY PATIENT WILL RESPOND EQUIVALENTLY OR IF SOME PATIENTS WILL BE PRONE TO OFF- TARGET, LIFE-THREATENING SIDE EFFECTS. WHAT IS NEEDED ARE TRANSLATIONALLY-RELEVANT TECHNOLOGIES THAT CAN MONITOR THE FATE OF CRISPR/CAS-EDITED CAR-T CELLS IN VIVO TO PROVIDE THE INFORMATION NEEDED TO UNDERSTAND PATIENT TREATMENT RESPONSE/NON-RESPONSE, RELAPSE AND/OR TOXICITY. THE LONG-TERM OBJECTIVE OF THIS APPLICATION IS TO DEVELOP MOLECULAR IMAGING REPORTER GENE TECHNOLOGIES FOR NON-INVASIVE VISUALIZATION OF TRAC-TARGETED CAR-T CELLS IN PATIENTS. SPECIFICALLY, WE PROPOSE TO DEVELOP NOVEL TRANSLATIONALLY-RELEVANT MAGNETIC RESONANCE IMAGING (MRI) AND POSITRON EMISSION TOMOGRAPHY (PET) REPORTER GENE ASSAYS TO NONINVASIVELY TRACK THE FATE OF TRAC-EDITED CAR-T CELLS OVER TIME AND TO VALIDATE THESE TECHNOLOGIES IN PRECLINICAL MOUSE MODELS. THE SPECIFIC AIMS OF THIS NEW APPLICATION ARE: TO COMPARE MINICIRCLE AND NON-INTEGRATING LENTIVIRAL CRISPR/CAS DONOR VECTORS FOR THEIR ABILITY TO EFFICIENTLY EDIT T CELLS AT THE TRAC LOCI WITH A CD19-TARGETED CAR (AIM 1.1); TO DEVELOP DONOR VECTORS CO-ENCODING OUR CAR, A BIOLUMINESCENCE REPORTER GENE, AND EITHER THE HUMAN MRI REPORTER ORGANIC ANION TRANSPORTER POLYPEPTIDE 1B3 (OATP1B3) OR THE PET REPORTER SODIUM IODIDE SYMPORTER (NIS), AND TO VALIDATE TRAC-EDITING AND FUNCTIONAL REPORTER EXPRESSION IN VITRO (AIM 1.2); TO EVALUATE THE SENSITIVITY OF OATP1B3-BASED MRI AND NIS-BASED PET FOR VISUALIZING CAR-T CELLS IN VIVO, AS WELL AS PERFORM LONGITUDINAL PET AND MRI OF CAR-T CELLS IN MOUSE MODELS OF B CELL MALIGNANCIES (AIM 2.1); AND FINALLY, TO DEVELOP A DUAL-REPORTER TRANSLATIONALLY-RELEVANT CRISPR/CAS SYSTEM AND EVALUATE THE ABILITY TO NONINVASIVELY MONITOR CAR-T CELLS IN MICE WITH BOTH PET AND MRI (AIM 2.2). THE SIGNIFICANCE OF THIS WORK WILL BE TO PROVIDE POWERFUL CELL TRACKING TECHNOLOGIES TO ALLOW THE FATE OF CRISPR/CAS-EDITED CAR-T CELLS, OR OTHER CRISPR/CAS-EDITED CELLULAR THERAPIES, TO BE MONITORED NONINVASIVELY IN PRECLINICAL MODELS AND PATIENTS. THIS INFORMATION WILL ALLOW MORE PRECISE MONITORING OF THESE TRANSFORMATIVE THERAPIES IN INDIVIDUAL PATIENTS TO BETTER ASSESS SAFETY AS WELL AS TO RELATE CELL BIODISTRIBUTION TO PATIENT OUTCOMES.
Department of the Interior
$503.2K
D18AC00035
Department of Defense
$479.6K
ADVANCED DEVELOPMENT OF A THERAPEUTIC, HUMANIZED, ANTI-INFLAMMATORY ANTIBODY
Department of Health and Human Services
$414.1K
MICROVASCULAR O2 DELIVERY: IMPACT OF ERYTHROCYTE-RELEASED ATP
Department of Health and Human Services
$314.6K
NON-INVASIVE MONITORING OF CRISPR/CAS-EDITED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELLS WITH REPORTER GENE-BASED MAGNETIC RESONANCE IMAGING AND POSITRON EMISSION TOMOGRAPHY
Department of Health and Human Services
$109.3K
ROLE OF OVO-LIKE 1 IN THE REGULATION OF HUMAN TROPHOBLAST DIFFERENTIATION
Department of Defense
$84.3K
USING GENETIC BUFFERING RELATIONSHIPS IDENTIFIED IN FISSION YEAST TO ELUCIDATE THE MOLECULAR PATHOLOGY OF TUBEROUS SCLEROSIS
Department of Health and Human Services
$74.1K
ENGINEERING A CHIMERIC SERPIN AS A PREVENTIVE THERAPEUTIC FOR ISCHEMIC STROKE
Department of Defense
$18.9K
CSP - INTERNATIONAL CONFERENCE ON AUDITORY CORTEX
Department of State
$8,000
TO FUND THE TRAVEL COSTS FOR UP TO FOUR U.S. SPEAKERS.
Department of State
$6,278
GRANT WILL SUPPORT U.S. RELATED CONFERENCE ENTITLED "STATES OF EMERGENCY: CRISIS PANIC AND NATION." THE CONFERENC WILL FOCUS ON HOW AMERICANS HAVE H
National Aeronautics and Space Administration
-$10.1K
EXTENSIVE METERIOD OBSERVATION
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2024 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: FORGN
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2023IRS e-File | $1.5B | $583.1M | $1.3B | $4.7B | $3.1B |
| 2022 | $1.3B | $531.8M | $1.2B | $4.3B | $2.5B |
| 2021 | $1.3B | $523.4M | $1.1B | $4.1B | $2.2B |
| 2020 | $1.2B | $530.9M | $1.1B |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
Financial data: IRS e-Filed Form 990 (Tax Year 2023)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Dr Alan Shepard | President & Vice Chancellor | 40 | $525.3K | $0 | $0 | $525.3K |
| Florentine Strzelcyzk | Provost & VP Academic | 40 | $345.1K | $0 | $0 | $345.1K |
| Lynn Logan | VP Operations & Finance | 40 | $338.6K | $0 | $0 | $338.6K |
| Penny Pexman | VP Research | 40 | $291.5K | $0 | $0 | $291.5K |
| Amy Bryson | University Secretary | 40 | $213.6K | $0 | $0 | $213.6K |
Dr Alan Shepard
President & Vice Chancellor
$525.3K
Hrs/Wk
40
Compensation
$525.3K
Related Orgs
$0
Other
$0
Florentine Strzelcyzk
Provost & VP Academic
$345.1K
Hrs/Wk
40
Compensation
$345.1K
Related Orgs
$0
Other
$0
Lynn Logan
VP Operations & Finance
$338.6K
Hrs/Wk
40
Compensation
$338.6K
Related Orgs
$0
Other
$0
Penny Pexman
VP Research
$291.5K
Hrs/Wk
40
Compensation
$291.5K
Related Orgs
$0
Other
$0
Amy Bryson
University Secretary
$213.6K
Hrs/Wk
40
Compensation
$213.6K
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Sharon Hodgson | Dean / Lawrence C Tapp Chair Of Leadership | 40 | $596.5K | $0 | $0 | $596.5K |
| Dr John Yoo | Dean/professor/medical Doctor | 40 | $584.8K | $0 | $0 | $584.8K |
| Dr Anthony Tang | Professor | 40 | $550K | $0 | $0 | $550K |
| Dr Stephen Williamson | Professor | 40 | $421K | $0 | $0 | $421K |
| Ruban Chelladurai | Avp Institutional Planning And Budgetting | 40 | $394.2K | $0 | $0 | $394.2K |
Sharon Hodgson
Dean / Lawrence C Tapp Chair Of Leadership
$596.5K
Hrs/Wk
40
Compensation
$596.5K
Related Orgs
$0
Other
$0
Dr John Yoo
Dean/professor/medical Doctor
$584.8K
Hrs/Wk
40
Compensation
$584.8K
Related Orgs
$0
Other
$0
Dr Anthony Tang
Professor
$550K
Hrs/Wk
40
Compensation
$550K
Related Orgs
$0
Other
$0
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Arzie Chant | Director | 5 | $0 | $0 | $0 | $0 |
| Beth Macdougall Shackleton | Director | 5 | $0 | $0 | $0 | $0 |
| Cameron Bailey | Director | 5 | $0 | $0 | $0 | $0 |
| Cecil Rorabeck | Director | 5 | $0 | $0 | $0 | $0 |
| David Simmonds | Director | 5 | $0 | $0 | $0 | $0 |
| Edmund Goehring | Director |
Arzie Chant
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Beth Macdougall Shackleton
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Cameron Bailey
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Individuals who previously served as officers or key employees.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Jeffrey O'Hagan | VP Advancement | 40 | $326.6K | $0 | $0 | $326.6K |
| Bryan Neff | Acting Vp, Research | 40 | $312.1K | $0 | $0 | $312.1K |
Jeffrey O'Hagan
VP Advancement
$326.6K
Hrs/Wk
40
Compensation
$326.6K
Related Orgs
$0
Other
$0
Bryan Neff
Acting Vp, Research
$312.1K
Hrs/Wk
40
Compensation
$312.1K
Related Orgs
$0
Other
$0
| $3.6B |
| $1.8B |
| 2019 | $1.2B | $528.7M | $1.1B | $3.5B | $1.8B |
| 2018 | $1.2B | $512.2M | $1.1B | $3.3B | $1.6B |
| 2017 | $1.2B | $501.8M | $1B | $3B | $1.4B |
| 2016 | $1.1B | $501.5M | $1B | $2.7B | $1.2B |
| 2015 | $1.1B | $490.6M | $995.3M | $2.7B | $1.1B |
| 2014 | $1.1B | $530.9M | $985.8M | $2.5B | $1.1B |
| 2013 | $1B | $520.3M | $939.9M | $2.1B | $729.4M |
| 2012 | $948.8M | $519.2M | $908.6M | $1.7B | $493.6M |
| 2021 | 990 | Data |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | — |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
Dr Stephen Williamson
Professor
$421K
Hrs/Wk
40
Compensation
$421K
Related Orgs
$0
Other
$0
Ruban Chelladurai
Avp Institutional Planning And Budgetting
$394.2K
Hrs/Wk
40
Compensation
$394.2K
Related Orgs
$0
Other
$0
| 5 |
| $0 |
| $0 |
| $0 |
| $0 |
| Effie Sapuridis | Director | 5 | $0 | $0 | $0 | $0 |
| Ethan Chen | Director | 5 | $0 | $0 | $0 | $0 |
| Geoff Pollock | Director | 5 | $0 | $0 | $0 | $0 |
| Greg Dick | Director | 5 | $0 | $0 | $0 | $0 |
| Josh Morgan | Director | 5 | $0 | $0 | $0 | $0 |
| Keith Gibbons | Chair | 5 | $0 | $0 | $0 | $0 |
| Kelly Meighen | Chancellor | 5 | $0 | $0 | $0 | $0 |
| Ken Yeung | Director | 5 | $0 | $0 | $0 | $0 |
| Kenisha Arora | Director | 5 | $0 | $0 | $0 | $0 |
| Lee Greenberg | Director | 5 | $0 | $0 | $0 | $0 |
| Lori Higgs | Director | 5 | $0 | $0 | $0 | $0 |
| Marlene Mcgrath | Director | 5 | $0 | $0 | $0 | $0 |
| Michelle Banik | Director | 5 | $0 | $0 | $0 | $0 |
| Sarah Shortreed | Vice-chair | 5 | $0 | $0 | $0 | $0 |
| Stephen Pitel | Director | 5 | $0 | $0 | $0 | $0 |
| Stephen Poloz | Director | 5 | $0 | $0 | $0 | $0 |
| Susan Bennett | Director | 5 | $0 | $0 | $0 | $0 |
| Susan Clarke | Director | 5 | $0 | $0 | $0 | $0 |
| Terry Rice | Director | 5 | $0 | $0 | $0 | $0 |
Cecil Rorabeck
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
David Simmonds
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Edmund Goehring
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Effie Sapuridis
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Ethan Chen
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Geoff Pollock
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Greg Dick
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Josh Morgan
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Keith Gibbons
Chair
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Kelly Meighen
Chancellor
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Ken Yeung
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Kenisha Arora
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Lee Greenberg
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Lori Higgs
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Marlene Mcgrath
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Michelle Banik
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Sarah Shortreed
Vice-chair
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Stephen Pitel
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Stephen Poloz
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Susan Bennett
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Susan Clarke
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Terry Rice
Director
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0